MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-09-2026
MacroGenics Accounts Receivables 2011-2026 | MGNX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables MacroGenics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.4 M | 4.31 M | 10.4 M | 56.2 M | 10.4 M | 23.1 M | 12.7 M | 29.6 M | 13.6 M | 2.76 M | 1.22 M | 2.94 M | 2 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 56.2 M | 1.22 M | 14 M |
Quarterly Accounts Receivables MacroGenics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 69.2 M | 12.5 M | 10.5 M | 4.31 M | 8.75 M | 6.19 M | - | 10.4 M | 25.3 M | 6.41 M | 36.2 M | 56.2 M | 13.8 M | 18.4 M | 14.9 M | 10.4 M | 13.8 M | 45.2 M | 7.15 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 2.94 M | 2.94 M | 2.94 M | 2.94 M | 2 M | 2 M | 2 M | - | 2.05 M | 2.05 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 69.2 M | 1.22 M | 14.2 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Benitec Biopharma
BNTC
|
33 K | $ 10.98 | -4.52 % | $ 452 M |  USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M |  Canada |
 |
Assembly Biosciences
ASMB
|
974 K | $ 28.46 | 3.45 % | $ 319 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
109 K | $ 1.37 | -4.2 % | $ 350 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | USA |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Calithera Biosciences
CALA
|
1.54 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
2.76 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
411 K | - | - | $ 3.74 B | USA |
 |
Compugen Ltd.
CGEN
|
2 M | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Coherus BioSciences
CHRS
|
17.8 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Clovis Oncology
CLVS
|
26.9 M | - | -7.23 % | $ 13 M | USA |
 |
Curis
CRIS
|
3.35 M | $ 0.77 | 1.89 % | $ 4.86 M | USA |